These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

35 related articles for article (PubMed ID: 34284141)

  • 1. MiR-599 targeting TOP2A inhibits the malignancy of bladder cancer cells.
    Zhang F; Wu H
    Biochem Biophys Res Commun; 2021 Sep; 570():154-161. PubMed ID: 34284141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of TOP2A in bladder urothelial carcinoma and potential molecular mechanisms.
    Zeng S; Liu A; Dai L; Yu X; Zhang Z; Xiong Q; Yang J; Liu F; Xu J; Xue Y; Sun Y; Xu C
    BMC Cancer; 2019 Jun; 19(1):604. PubMed ID: 31216997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Propofol modulates the proliferation, invasion and migration of bladder cancer cells through the miR‑145‑5p/TOP2A axis.
    Du Y; Zhang X; Zhang H; Chen Y; Zhu S; Shu J; Pan H
    Mol Med Rep; 2021 Jun; 23(6):. PubMed ID: 33846791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MiR-302b regulates cell functions and acts as a potential biomarker to predict recurrence in bladder cancer.
    Li Z; Zhou L; Lin C; Pan X; Xie J; Zhao L; Quan J; Xu J; Guan X; Xu W; Li H; Chen Y; Lai Y
    Life Sci; 2018 Sep; 209():15-23. PubMed ID: 30075175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup.
    Labbé DP; Sweeney CJ; Brown M; Galbo P; Rosario S; Wadosky KM; Ku SY; Sjöström M; Alshalalfa M; Erho N; Davicioni E; Karnes RJ; Schaeffer EM; Jenkins RB; Den RB; Ross AE; Bowden M; Huang Y; Gray KP; Feng FY; Spratt DE; Goodrich DW; Eng KH; Ellis L
    Clin Cancer Res; 2017 Nov; 23(22):7072-7083. PubMed ID: 28899973
    [No Abstract]   [Full Text] [Related]  

  • 6. Fe
    Grammatikaki S; Bala VM; Katifelis H; Lampropoulou DI; Mukha I; Vityuk N; Lagopati N; Kouloulias V; Aravantinos G; Gazouli M
    In Vivo; 2024; 38(4):1665-1670. PubMed ID: 38936909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PRRX1-TOP2A interaction is a malignancy-promoting factor in human malignant peripheral nerve sheath tumours.
    Takihira S; Yamada D; Osone T; Takao T; Sakaguchi M; Hakozaki M; Itano T; Nakata E; Fujiwara T; Kunisada T; Ozaki T; Takarada T
    Br J Cancer; 2024 May; 130(9):1493-1504. PubMed ID: 38448751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AURKB promotes bladder cancer progression by deregulating the p53 DNA damage response pathway via MAD2L2.
    Li L; Jiang P; Hu W; Zou F; Li M; Rao T; Ruan Y; Yu W; Ning J; Cheng F
    J Transl Med; 2024 Mar; 22(1):295. PubMed ID: 38515112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MiR-3960 inhibits bladder cancer progression via targeting of DEXI.
    Li W; Wang Z; Jiang Z; Yan Y; Yao X; Pan Z; Chen L; Wang F; Wang M; Qin Z
    Biochem Biophys Res Commun; 2023 Aug; 668():8-18. PubMed ID: 37230046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MiR-582-5p Inhibits Bladder Cancer-Genesis by Suppressing TTK Expression.
    Tian Y; Guan Y; Su Y; Luo W; Yang G; Zhang Y
    Cancer Manag Res; 2020; 12():11933-11944. PubMed ID: 33244270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential Signature Therapeutic Biomarkers TOP2A, MAD2L1, and CDK1 in Colorectal Cancer: A Systems Biomedicine-Based Approach.
    Priyamvada P; Ramaiah S
    Biochem Genet; 2024 Jun; 62(3):2166-2194. PubMed ID: 37884851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioinformatic Analysis of Topoisomerase IIα Reveals Interdomain Interdependencies and Critical C-Terminal Domain Residues.
    Endsley CE; Moore KA; Townsley TD; Durston KK; Deweese JE
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding the role of transmembrane 9 superfamily member 1 in bladder cancer pathogenesis.
    Gade VKV; Yadav BS
    World J Clin Oncol; 2024 Apr; 15(4):468-471. PubMed ID: 38689631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression and potential molecular mechanism of TOP2A in metastasis of non-small cell lung cancer.
    Wu J; Li W; Zhang X; Shi F; Jia Q; Wang Y; Shi Y; Wu S; Wang X
    Sci Rep; 2024 May; 14(1):12228. PubMed ID: 38806610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of TOP2A and ADH1B with lipid levels and prognosis in patients with lung adenocarcinoma and squamous cell carcinoma.
    Yin D; Zhang Y; Li H; Cheng L
    Clin Respir J; 2023 Dec; 17(12):1301-1315. PubMed ID: 37985446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of topoisomerase 2A as a novel bone metastasis-related gene in liver hepatocellular carcinoma.
    Feng J; Wei X; Liu Y; Zhang Y; Li G; Xu Y; Zhou P; Zhang J; Han X; Zhang C; Zhang Y; Wang G
    Aging (Albany NY); 2023 Nov; 15(22):13010-13040. PubMed ID: 37980167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-30c-2-3p suppresses the proliferation of human renal cell carcinoma cells by targeting TOP2A.
    Huang X; Jia Y; Shi H; Fan H; Sun L; Zhang H; Wang Y; Chen J; Han J; Wang M; Du J; Zhang J
    Asian Biomed (Res Rev News); 2023 Jun; 17(3):124-135. PubMed ID: 37818158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AURKA, TOP2A and MELK are the key genes identified by WGCNA for the pathogenesis of lung adenocarcinoma.
    Xu Y; Wang S; Xu B; Lin H; Zhan N; Ren J; Song W; Han R; Cheng L; Zhang M; Zhang X
    Oncol Lett; 2023 Jun; 25(6):238. PubMed ID: 37153047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circular RNA Ubiquitin-associated Protein 2 Silencing Suppresses Bladder Cancer Progression by Downregulating DNA Topoisomerase 2-alpha Through Sponging miR-496.
    Fu Y; Liu K; Zhao L; Jiang X; Wang T
    Eur Urol Open Sci; 2023 Apr; 50():31-42. PubMed ID: 37101770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Integrated Bioinformatics Analysis towards the Identification of Diagnostic, Prognostic, and Predictive Key Biomarkers for Urinary Bladder Cancer.
    Sarafidis M; Lambrou GI; Zoumpourlis V; Koutsouris D
    Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 2.